28. Juni 2024 – The European Medicines Agency (EMA) and the national Heads of Medicines Agencies (HMA) have issued recommendations to address the shortages of GLP-1 receptor agonists like Ozempic and Saxenda, used for diabetes and weight management. Rising demand and manufacturing constraints have led to EU-wide shortages since 2022. Off-label use for cosmetic weight loss is worsening the situation.

Key actions include increasing manufacturing capacity, optimizing distribution, and prioritizing patients with the greatest need. The EMA emphasizes that GLP-1 receptor agonists are not approved for, and should not be used for, cosmetic weight loss, i.e. use for weight loss in people without obesity or people with overweight who do not have weight-related health problems. Healthcare professionals should consider offering these people lifestyle advice instead.

For more information, see here.